Core Viewpoint - Yiteng Pharmaceutical Group completed a reverse acquisition of Jiahe Biopharma, marking the establishment of Yiteng Jiahe Pharmaceutical Group and entering a new phase of strategic integration and development [1][2]. Group 1: Company Overview - Yiteng Pharmaceutical, founded in 2001, has developed a comprehensive value chain in R&D, production, and commercialization, focusing on oncology, autoimmune diseases, cardiovascular, respiratory, and anti-infection treatments [3]. - The company has a solid market foundation with approximately 1,000 sales representatives covering 31 provinces, 17,000 hospitals, 19,000 pharmacies, and 188 commercial companies as of June 30, 2025 [3]. Group 2: Strategic Transformation - Yiteng Pharmaceutical transitioned from a traditional CSO model to a dual-driven strategy of acquiring mature products and licensing innovative drugs, evolving into a specialty pharmaceutical company [4]. - The year 2019 was pivotal for Yiteng, completing significant acquisitions that transformed it from a channel agent to a product holder and manufacturer, establishing it as a true pharmaceutical enterprise [4]. Group 3: Financial Performance - Yiteng's revenue is projected to grow from 2.074 billion RMB in 2022 to 2.546 billion RMB in 2024, with net profits of approximately 306 million RMB, 308 million RMB, and 388 million RMB for the respective years [6]. - As of June 30, 2025, the company had cash and cash equivalents of 778 million RMB, a 54.1% increase year-on-year, with a net cash flow from operating activities reaching 916 million RMB in 2024 [6]. Group 4: Industry Context - The Chinese biopharmaceutical industry is undergoing a capital winter, with a significant decline in financing cases and amounts, which presents both challenges and opportunities for companies like Yiteng with strong commercial capabilities and cash flow [7][6]. - The market for innovative drugs is shifting towards a focus on R&D and clinical value, with Yiteng's acquisition of Jiahe Biopharma seen as a strategic move to enhance its capabilities in the oncology and autoimmune sectors [7][25]. Group 5: Acquisition of Jiahe Biopharma - Jiahe Biopharma, initially valued at over 14 billion HKD, saw its market value drop nearly 90% to 1.6 billion HKD due to setbacks in its core product, a PD-1 monoclonal antibody [9][8]. - The merger allows Yiteng to leverage Jiahe's promising oncology pipeline, particularly the CDK4/6 inhibitor GB491, which has received regulatory approval and is entering commercialization [11][25]. Group 6: Future Prospects - The merger is expected to create a synergistic effect, with Yiteng's established sales network providing a "highway" for GB491's market penetration, while also ensuring financial support for Jiahe's future pipeline development [25][26]. - The combined entity aims to navigate the competitive landscape of oncology treatments, with a focus on innovative therapies that meet clinical needs and market viability [27][26].

Group 1 - Yiteng Pharmaceutical Group Co., Ltd. completed a reverse acquisition with Jiahe Biopharmaceuticals, marking the establishment of Yiteng Jiahe Pharmaceutical Group Co., Ltd. and entering a new phase of strategic integration and development [1][2] - The Chinese biopharmaceutical industry is characterized by intense competition, with companies typically following linear paths from R&D to commercialization, but Yiteng Pharmaceutical has chosen a reverse path, starting from a solid commercialization backend to integrate production and R&D [2][6] - Yiteng Pharmaceutical, founded in 2001, has built a comprehensive value chain in R&D, production, and commercialization, focusing on oncology, autoimmune diseases, cardiovascular, respiratory, and anti-infection treatments [2][3] Group 2 - The company has established a balanced product portfolio, with three core commercial products: Vancomycin, Cefaclor, and Fluticasone, alongside three innovative products, providing growth momentum for future development [3][5] - Yiteng Pharmaceutical's revenue is projected to grow from 2.074 billion RMB in 2022 to 2.546 billion RMB in 2024, with net profits of approximately 306 million RMB, 308 million RMB, and 388 million RMB for the same years [5] - The company has a strong cash flow, with cash and cash equivalents reaching 778 million RMB as of June 30, 2025, a 54.1% increase year-on-year, primarily driven by its core business operations [5] Group 3 - Jiahe Biopharmaceuticals, initially valued at over 14 billion HKD, saw its market value shrink by nearly 90% to 1.6 billion HKD due to setbacks in the approval process for its core product, GB226 [7][8] - The company has shifted its R&D focus to developing GB491, a CDK4/6 inhibitor for breast cancer, and three new antibody drugs, aiming to regain market traction [8][10] - GB491 has received approval for two indications and is now in the commercialization phase, with significant market potential in the competitive breast cancer treatment landscape [10][11] Group 4 - The merger between Yiteng Pharmaceutical and Jiahe Biopharmaceuticals is seen as a strategic move to leverage Yiteng's strong commercialization capabilities to enhance the market presence of Jiahe's products, particularly GB491 [25][26] - The combined entity aims to create a comprehensive commercial and R&D ecosystem, addressing the challenges faced by Jiahe in commercializing its innovative products [23][25] - The merger is expected to provide a robust platform for future growth, with Yiteng's established sales network facilitating the rapid market entry of Jiahe's products [25][26] Group 5 - The merger represents a unique case in the Chinese biopharmaceutical landscape, showcasing a pragmatic approach to building a sustainable business model that integrates commercialization, production, and R&D [27] - The combined company is positioned to navigate the current capital winter in the pharmaceutical industry, leveraging its strong cash flow and established market presence to drive innovation and growth [26][27] - This strategic integration is anticipated to enhance the competitive edge of the new entity in the rapidly evolving biopharmaceutical market, emphasizing the importance of diverse growth paths in the industry [27]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業 (開 曼 )控股有限公司 (the "Company") (Incorpora ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內容而 引致的任何損失承擔任何責任。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （「本公司」） （於開曼群島註冊成立的有限公司） （股份代號：6998） 的聆訊後資料集 警告 閣下如已將名下之嘉和生物藥業（開曼）控股有限公司股份全部售出或轉讓，應立即將本通函連同隨附之代表委任表格，送交買主或承讓 人或經手買賣或轉讓之銀行、股票經紀或其他代理，以便轉交買主或承讓人。 本通函僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作向香港 ...

The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its joint sponsors or advisers that: GENOR ...

Core Insights - Candid Therapeutics, Inc. has made progress in clinical evaluation of GB261, a novel T cell engager for autoimmune diseases, with the first patients receiving treatment and showing good tolerance [1] - The subcutaneous formulation of GB261 has been established, which is a bispecific antibody targeting CD20 on B cells and CD3 on T cells, designed to mediate T cell cytotoxicity against CD20-expressing B cells [1] - GB261 has a low affinity for CD3, reducing the risk of T cell overactivation while maintaining effective and selective B cell clearance [1] Company Overview - Candid Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming treatment methods for autoimmune and inflammatory diseases through its novel T cell engager platform [2] - The company has granted a global exclusive license to TRC 2004, Inc. for the development and commercialization of GB261, excluding mainland China, Hong Kong, Macau, and Taiwan [2] - Following the merger of Candid Therapeutics, Inc. and TRC 2004, Inc. in August 2024, the rights will be transferred to Candid Therapeutics, which is led by an experienced management team including CEO Dr. Ken Song [2]

合并后公司拥有以景助达及GB491治疗晚期或转移性HR+/HER2-乳腺癌的协同专营权。 本文为IPO早知道原创 嘉和生物向亿腾医药股东发行新股作为对价， 亿腾医药、嘉和生物在此次交易中的股权价值分别为 6.77亿美元和1.97亿美元。 亿腾医药股东将持有 合并公司 77.43%的股份，成为 合并公司的 控股 股东，而嘉和生物的股东则持有 其余 的 22.57%股份。 亿腾医药 从一家 CSO发展成综合型生物医药公司， 专注于在中国研究、开发及商业化具有巨大市 场需求的治疗药物。公司通过向跨国公司收购品牌药物资产，以及从全球生物制药公司授权引进创新 专利药物的开发及商业化权利，已建立多元化产品组合 ， 主要覆盖 抗感染、 CVD及呼吸系统 疾病 。 其主要产品包括 3 款 原研药 稳可信、希刻劳 、 亿瑞平 、 2款创新药 Vascepa 、 Mulpleta ， 及 其他产品包括 H景助达、罗可曼均已经实现商业化。 同时 ，亿腾 医药通过 获得跨国公司转让生产设施及管理体系并实施运营，拥有了 符合国际标准 的 制造、供应链管理、技术转移及质量控制体系。 公司在中国 31个省份拥有1000名销售代表，覆盖约1 ...